The reference site for Lasofoxifene

Lasofoxifene (INN) (brand name Fablyn) is a non-steroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy

WHAT IS LASOFOXIFENE?

Lasofoxifene (Oporia®) is a selective estrogen receptor modulator (SERM) under development for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.

Osteoporosis affects some 8 million American women. An additional 22 million women are estimated to have low bone mass, placing them at increased risk of osteoporosis. In the U.S., osteoporosis is responsible for more than 1.5 million fractures per year.

Vaginal dryness becomes increasingly more common throughout the menopausal transition. SERMs may offer benefits beyond just the bone effects provided by other treatment options, such as bisphosphonates.

 

Brand Name(s): Oporia
CAS nº: 180916-16-9
(la so fox ih feen)

 

Product Info

The sections below will provide you with more specific information and guidelines related to lasofoxifene and its correct use. Please read them carefully.

FDA Information

In September 2005, Pfizer Inc. received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (Oporia®), a selective estrogen receptor modulator for the prevention of osteoporosis.

Pfizer said that it will be reviewing its submission with the FDA and considering various possible courses of action.

Please visit the official site of the FDA for further information.

Why is this medication prescribed?

Lasofoxifene (Oporia®) is a selective estrogen receptor modulator (SERM) under development for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.

Osteoporosis affects some 8 million American women. An additional 22 million women are estimated to have low bone mass, placing them at increased risk of osteoporosis. In the U.S., osteoporosis is responsible for more than 1.5 million fractures per year.

On the other hand, vaginal dryness becomes increasingly more common throughout the menopausal transition. SERMs may offer benefits beyond just the bone effects provided by other treatment options, such as bisphosphonates.

Other uses for this medicine

Lasofoxifene is currently under development, and not yet available on the market.

Alternative uses for this medication have not been defined, and scientific research and studies are currently still in process.

Dosage and using this medicine

Lasofoxifene is currently under development.

Information regarding dosage and how this medication is to be administered have not been finalized. This information will be included in this section once this medication is available on the market to consumers.

What special precautions should I follow?

BEFORE TAKING LASOFOXIFENE:

Lasofoxifene is currently under development, and detailed information regarding precautions that should be taken, and drug interaction with other medications, will be included in this section once it is available on the market.

What should I do if I forget a dose?

Information regarding a missed dose will be included following FDA approval of lasofoxifene (currently under development).

What side effects can this medication cause?

Lasofoxifene is currently under development, and not yet available on the market.

Specific guidelines on this medication’s side effects and what patients should look out for have not yet been concluded, but will be included in this section once it has received FDA approval.

What storage conditions are needed for this medicine?

Specific storage indications related to this medication will be included shortly.

In case of an emergency/overdose

Lasofoxifene is currently under development, and information regarding overdose symptoms and emergency procedures are not yet available.

However, if you suspect of an overdose whilst using any form of medication, call your local poison control center on 1-800-222-1222. Moreover, if the victim has collapsed or is not breathing, please call the local emergency services immediately on 911.

Product Images

PICTURES OF LASOFOXIFENE PILLS

Lasofoxifene is currently undergoing clinical trials and development, and is not yet available on the market.

No product images are currently available.

 

Contact us